Trial Profile
An Open-Label, Single-Dose, Randomized, Crossover Study to Compare the Bioavailability of the Intranasal Administration of 20 mg OPTINOSE SUMATRIPTAN With 20 mg IMITREX (Sumatriptan) Nasal Spray, 100 mg IMITREX (Sumatriptan) Oral Tablet and 6 mg IMITREX (Sumatriptan) Subcutaneous Injection in Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Sumatriptan (Primary) ; Sumatriptan (Primary) ; Sumatriptan (Primary)
- Indications Migraine
- Focus Pharmacokinetics
- 28 Jun 2013 Results presented at the 2013 International Headache Congress, according to an Optinose media release.
- 02 Oct 2012 Results have been reported in an OptiNose media release.
- 28 Feb 2012 Actual patients number is 20 as reported by ClinicalTrials.gov.